• Full Text
  • Scholarly Journal

Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials

Stohl, William; Merrill, Joan T; Looney, R John; Buyon, Jill; Wallace, Daniel J ; et al.Stohl, William; Merrill, Joan T; Looney, R John; Buyon, Jill; Wallace, Daniel J; Weisman, Michael H; Ginzler, Ellen M; Cooke, Blaire; Holloway, Donna; Kaliyaperumal, Arunan; View all authors.  Arthritis Research & Therapy; London Vol. 17,  (2015).